These included a patient with liposarcoma harboring a BRCA2 mutation treated with PARP inhibitors (PFS 29.5 months) and a patient with an NTRK1 fusion treated with larotrectinib (PFS 57.7 months). This evidence concerns the gene BRCA2 and liposarcoma.